A Phase II Study of AK146D1 Mono or Combined With AK112 in Advanced Urothelial Carcinoma

NCT07636772 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

132

Enrollment

INDUSTRY

Sponsor class

Conditions

Urothelial Carcinoma (UC)

Interventions

DRUG: AK146D1 for injection
DRUG: AK112 Injection

Sponsor

Akeso